Iovance Biotherapeutics, Inc. (LON:0JDK)
2.320
0.00 (0.00%)
At close: Sep 17, 2025
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $59.95M USD in the quarter ending June 30, 2025, with 92.73% growth. This brings the company's revenue in the last twelve months to $241.53M, up 636.99% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$241.53M
Revenue Growth
+636.99%
P/S Ratio
3.34
Revenue / Employee
$288.22K
Employees
838
Market Cap
587.99M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
Dec 31, 2023 | 1.19M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Iovance Biotherapeutics News
- 19 days ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 23 days ago - Why Iovance Biotherapeutics Stock Got Mashed on Monday - The Motley Fool
- 26 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 - Seeking Alpha
- 4 weeks ago - Why Iovance Biotherapeutics Stock Was Climbing Today - The Motley Fool
- 4 weeks ago - Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - GlobeNewsWire
- 5 weeks ago - Why Iovance Biotherapeutics Stock Plummeted Today - The Motley Fool
- 5 weeks ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha